RT Journal Article
SR Electronic
T1 Multiparametric MRI Along with Machine Learning Informs on Molecular Underpinnings, Prognosis, and Treatment Response in Pediatric Low-Grade Glioma
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.04.18.24306046
DO 10.1101/2024.04.18.24306046
A1 Kazerooni, Anahita Fathi
A1 Kraya, Adam
A1 Rathi, Komal S.
A1 Kim, Meen Chul
A1 Vossough, Arastoo
A1 Khalili, Nastaran
A1 Familiar, Ariana
A1 Gandhi, Deep
A1 Khalili, Neda
A1 Kesherwani, Varun
A1 Haldar, Debanjan
A1 Anderson, Hannah
A1 Jin, Run
A1 Mahtabfar, Aria
A1 Bagheri, Sina
A1 Guo, Yiran
A1 Li, Qi
A1 Huang, Xiaoyan
A1 Zhu, Yuankun
A1 Sickler, Alex
A1 Lueder, Matthew R.
A1 Phul, Saksham
A1 Koptyra, Mateusz
A1 Storm, Phillip B.
A1 Ware, Jeffrey B.
A1 Song, Yuanquan
A1 Davatzikos, Christos
A1 Foster, Jessica
A1 Mueller, Sabine
A1 Fisher, Michael J.
A1 Resnick, Adam C.
A1 Nabavizadeh, Ali
YR 2024
UL http://medrxiv.org/content/early/2024/05/30/2024.04.18.24306046.abstract
AB In this study, we present a comprehensive radiogenomic analysis of pediatric low-grade gliomas (pLGGs), combining treatment-naïve multiparametric MRI and RNA sequencing. We identified three immunological clusters using XCell enrichment scores, highlighting an ‘immune-hot’ group correlating with poorer prognosis, suggesting potential benefits from immunotherapies. A radiomic signature predicting immunological profiles showed balanced accuracies of 81.5% and 84.4% across discovery and replication cohorts, respectively. Our clinicoradiomic model predicted progression-free survival with concordance indices of 0.71 and 0.77 in these cohorts, and the clinicoradiomic scores correlated with treatment response (p = 0.001). We also explored germline variants and transcriptomic pathways related to clinicoradiomic risk, identifying those involved in tumor growth and immune responses. This is the first radiogenomic analysis in pLGGs that enhances prognostication by prediction of immunological profiles, assessment of patients’ risk of progression, prediction of treatment response to standard-of-care therapies, and early stratification of patients to identify potential candidates for novel therapies targeting specific pathways.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by National Institute of Health Grant Fundings 75N91019D00024, Supplement 3U2CHL156291-03S2, and 75N91019D00024.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Children's Brain Tumor Network (CBTN)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes